KRAS Mutation Detection with Reflex to BRAF Codon 600 Mutation Detection
2001932
 
Ordering Recommendation
Determine eligibility for anti-EGFR (cetuximab and panitumumab) therapy in patients with metastatic colorectal cancer.
Mnemonic
KRAS RFLX
Methodology
Polymerase Chain Reaction/Pyrosequencing
Performed
DNA isolation: Sun-Sat
Assay:
Mon, Wed, Fri
Reported
10-14 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Tumor tissue.  
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect paraffin block from excessive heat. Transport tissue block or 5 unstained 5-micron slides. (Min: 3 slides). Transport block and/or slide(s) in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.  
Storage/Transport Temperature
Room temperature or refrigerated. Ship in cooled container during summer months.  
Unacceptable Conditions
Frozen specimens. Specimens fixed/processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). Less than 25 percent tumor in tissue. Decalcified specimens.  
Remarks
Include surgical pathology report. Tissue block will be returned after testing.  
Stability
bient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable  
Reference Interval
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Note
This test detects mutations in codons 12, 13, and 61. If KRAS is not detected, BRAF codon 600 Mutation Detection will be performed. Additional charges apply.
CPT Code(s)
88381; 81275; 81403; If reflexed, add 81210
Components
Component Test Code*Component Chart Name
0040249KRAS Mutation Detection
2002148Block ID
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • Anti-EGFR therapy eligibility
  • anti-EGFR therapy resistance testing
  • BRAF codon 600
  • Cetuximab (Erbitux)
  • KRAS codons 12, 13, 61
  • Panitumumab (Vectibix)
  • RAS